Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research Continue Reading
New AJPC Study Examines How PREVENT Equations Translate Cardiovascular Risk Factors into Predicted CVD Risk Continue Reading
AJPC Publishes POLY-ACS Trial Demonstrating Feasibility of Polypill Strategy After Acute Coronary Syndrome Continue Reading
Chiesi Global Rare Diseases Announces FDA Approval of JUXTAPID® (lomitapide) Capsules for Pediatric Use in Homozygous Familial Hypercholesterolemia (HoFH) Continue Reading
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) Continue Reading
Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG) Continue Reading
On February 12, 2026, the FDA approved a new indication for pediatric patients aged 12 years and older with heterozygous familial hypercholesterolemia (HeFH), and a new indication for pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH). Continue Reading
American Journal of Preventive Cardiology Publishes Landmark Study on Sex Differences in Homozygous Familial Hypercholesterolemia in First Issue Under New Editor-in-Chief Continue Reading
The ASPC 2026 Congress on CVD Prevention will be held in-person at The Phoenician in Scottsdale, AZ from July 31 - August 2, 2026! Continue Reading
Boehringer Ingelheim and the Detect the SOS Collective, a group of professional organizations, advocates, patients and caregivers, launched a new public health mission: elevate awareness of urine albumin-to-creatinine ratio (uACR) screening to help uncover hidden risks for chronic kidney disease (CK Continue Reading
Where are cholesterol guidelines headed, and what must the clinical and prevention community do to keep up? Continue Reading
The U.S. Food and Drug Administration today awarded national priority vouchers under the Commissioner’s National Priority Voucher (CNPV) pilot program to two investigational products for their potential to increase access through affordability for American patients. Continue Reading
